{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Virus+Shedding&page=2",
    "query": {
      "condition": "Virus Shedding",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Virus+Shedding&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-07-24T03:38:21.625Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00362297",
      "title": "Randomized Trial to Evaluate Suppressive Effect of High-Dose Acyclovir Versus Once-Daily Valacyclovir on Persons With HSV-2",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Genital Herpes"
      ],
      "interventions": [
        {
          "name": "acyclovir",
          "type": "DRUG"
        },
        {
          "name": "valacyclovir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 31,
      "start_date": "2006-09",
      "completion_date": "2011-09",
      "has_results": true,
      "last_update_posted_date": "2021-11-18",
      "last_synced_at": "2026-07-24T03:38:21.625Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00362297"
    },
    {
      "nct_id": "NCT04542993",
      "title": "Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Covid19",
        "SARS-CoV Infection"
      ],
      "interventions": [
        {
          "name": "Zinc Picolinate",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Resveratrol",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Zinc Picolinate Placebo",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Resveratrol Placebo",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Swedish Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 45,
      "start_date": "2020-09-08",
      "completion_date": "2021-02-05",
      "has_results": false,
      "last_update_posted_date": "2022-07-29",
      "last_synced_at": "2026-07-24T03:38:21.625Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04542993"
    },
    {
      "nct_id": "NCT06538480",
      "title": "Zopa Retreatment and Vector Shedding in Adults With RRP",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Recurrent Respiratory Papillomatosis",
        "Papillomavirus Infection",
        "Papillomaviridae"
      ],
      "interventions": [
        {
          "name": "Zopapogene imadenovec (Zopa)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Precigen, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2024-07-11",
      "completion_date": "2028-12-02",
      "has_results": false,
      "last_update_posted_date": "2025-12-15",
      "last_synced_at": "2026-07-24T03:38:21.625Z",
      "location_count": 3,
      "location_summary": "Atlanta, Georgia • Bethesda, Maryland • Cincinnati, Ohio",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06538480"
    },
    {
      "nct_id": "NCT04405739",
      "title": "The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "SARS-CoV 2"
      ],
      "interventions": [
        {
          "name": "EIDD-2801",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ridgeback Biotherapeutics, LP",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 71,
      "start_date": "2020-06-16",
      "completion_date": "2022-02-21",
      "has_results": true,
      "last_update_posted_date": "2023-03-23",
      "last_synced_at": "2026-07-24T03:38:21.625Z",
      "location_count": 11,
      "location_summary": "Los Angeles, California • Chicago, Illinois • Oak Lawn, Illinois + 7 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Oak Lawn",
          "state": "Illinois"
        },
        {
          "city": "Park Ridge",
          "state": "Illinois"
        },
        {
          "city": "Shreveport",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04405739"
    },
    {
      "nct_id": "NCT00192140",
      "title": "Trial to Assess the Shedding,Immunogenicity, and Safety of FluMist Administered to Healthy Individuals 5-49 Years of Age",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "FluMist",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "MedImmune LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "5 Years to 49 Years"
      },
      "enrollment_count": 345,
      "start_date": "2004-06",
      "completion_date": "2005-01",
      "has_results": false,
      "last_update_posted_date": "2007-12-28",
      "last_synced_at": "2026-07-24T03:38:21.625Z",
      "location_count": 11,
      "location_summary": "Miami, Florida • Chicago, Illinois • Bardstown, Kentucky + 8 more",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Bardstown",
          "state": "Kentucky"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00192140"
    },
    {
      "nct_id": "NCT04399356",
      "title": "Niclosamide for Mild to Moderate COVID-19",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "Niclosamide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Telehealth monitoring",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Tufts Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 73,
      "start_date": "2020-10-01",
      "completion_date": "2021-08-19",
      "has_results": true,
      "last_update_posted_date": "2022-04-12",
      "last_synced_at": "2026-07-24T03:38:21.625Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04399356"
    },
    {
      "nct_id": "NCT00686075",
      "title": "A Study to Evaluate the Safety, Tolerability, Immunogenicity and Vaccine-like Viral Shedding of MEDI-534, Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy 6 to <24 Month-old Children and in 2 Month-old Infants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "MEDI-534, Cohort 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo, Cohort 1",
          "type": "OTHER"
        },
        {
          "name": "MEDI-534, Cohort 2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo, Cohort 2",
          "type": "OTHER"
        },
        {
          "name": "MEDI-534, Cohort 3",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo, Cohort 3",
          "type": "OTHER"
        },
        {
          "name": "MEDI-534, Cohort 4",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo, Cohort 4",
          "type": "OTHER"
        },
        {
          "name": "MEDI-534, Cohort 5",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo, Cohort 5",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "MedImmune LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "2 Months",
        "maximum_age": "23 Months",
        "sex": "ALL",
        "summary": "2 Months to 23 Months"
      },
      "enrollment_count": 1338,
      "start_date": "2008-06",
      "completion_date": "2012-08",
      "has_results": true,
      "last_update_posted_date": "2014-09-26",
      "last_synced_at": "2026-07-24T03:38:21.625Z",
      "location_count": 51,
      "location_summary": "Mobile, Alabama • Bentonville, Arkansas • Little Rock, Arkansas + 44 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Bentonville",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Anaheim",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00686075"
    },
    {
      "nct_id": "NCT00306293",
      "title": "VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Herpes Labialis"
      ],
      "interventions": [
        {
          "name": "valacyclovir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 70,
      "start_date": "2006-02-20",
      "completion_date": "2006-11-27",
      "has_results": true,
      "last_update_posted_date": "2018-03-23",
      "last_synced_at": "2026-07-24T03:38:21.625Z",
      "location_count": 18,
      "location_summary": "Anaheim, California • Carmichael, California • Fair Oaks, California + 14 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Carmichael",
          "state": "California"
        },
        {
          "city": "Fair Oaks",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00306293"
    },
    {
      "nct_id": "NCT02484417",
      "title": "Respiratory Syncytial Virus Human Challenge in Healthy Adult Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Upper Respiratory Tract Infection"
      ],
      "interventions": [
        {
          "name": "RSV A2",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 32,
      "start_date": "2015-07-21",
      "completion_date": "2016-08-10",
      "has_results": false,
      "last_update_posted_date": "2026-03-10",
      "last_synced_at": "2026-07-24T03:38:21.625Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02484417"
    },
    {
      "nct_id": "NCT04832932",
      "title": "The COVID-19 Back-to-Normal Study: Analysis of Multiple Outcomes",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "COVID-19 Vaccines"
      ],
      "interventions": [
        {
          "name": "COVID-19 vaccines",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Mebo Research, Inc.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2000,
      "start_date": "2021-01-05",
      "completion_date": "2025-01-05",
      "has_results": false,
      "last_update_posted_date": "2024-01-26",
      "last_synced_at": "2026-07-24T03:38:21.625Z",
      "location_count": 2,
      "location_summary": "Miami, Florida • Vonore, Tennessee",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Vonore",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04832932"
    }
  ]
}